. home.aspx



Pitching accuracy rates of over 99% for multiple cancer screens, Thrive launches with $110 million

May 31, 2019 / Jonathan Shieber

For more than 25 years the founders of Thrive Earlier Detection have been researching ways to improve the accuracy of liquid biopsy tests.The fruits of that labor from Dr. Bert Vogelstein, Dr. Kenneth Kinzler and Dr. Nickolas Papadopoulos  all professors and researchers at Johns Hopkins University is CancerSEEK, a liquid biopsy test that has demonstrated specificity of over 99% in a retrospective study published by Science.By minimizing false positives in cancer screening tools and providing a test with proven accuracy, doctors can take treatment actions earlier, which can lead to better survival rates for cancer patients.